TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07868172: A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GST101 in Participants With RAS-Mutant Advanced Solid Tumors

Sponsor: Genuine Seed Therapeutics (Zhuhai) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 172 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07868172 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07868172 Rescue Dossier →